Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Akesis commences AKP-020 dosing in phase IIa clinical trial in type 2 diabetes

Feb. 26, 2008

Novel agents for lipoprotein disorders imparted in a recent patent

Feb. 26, 2008

Eucreas, a single-tablet combination of Galvus and metformin, approved in EU

Feb. 26, 2008

Lilly launches the KwikPen insulin pen prefilled with Humalog and Humalog mixtures

Feb. 26, 2008

Sosei initiates a phase III trial for NorLevo

Feb. 25, 2008

EMEA recommends marketing authorization of Ipsen's Adenuric

Feb. 25, 2008

Acceleron and Celgene enter collaboration for ACE-011 cancer-related bone loss

Feb. 25, 2008

Lilly receives positive opinion from the EMEA for Forsteo in GIO

Feb. 22, 2008

Sciele Pharma launches LifeCycle Pharma's cholesterol-lowering Fenoglide in the U.S.

Feb. 22, 2008

ConjuChem initiates phase II PC-DAC:Exendin-4 study

Feb. 22, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...